tetano
Editor, Senior Moderator
Pharmacol Rep
. 2023 Jun 24.
doi: 10.1007/s43440-023-00506-z. Online ahead of print. Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments
Raj Singh[SUP] #[/SUP][SUP] 1 [/SUP], Parth Malik[SUP] #[/SUP][SUP] 2 [/SUP], Mukesh Kumar[SUP] 1 [/SUP], Raman Kumar[SUP] 1 [/SUP], Md Shamshir Alam[SUP] 3 [/SUP], Tapan Kumar Mukherjee[SUP] 4 5 [/SUP]
Affiliations
The earliest documented COVID-19 case caused by the SARS-CoV-2 coronavirus occurred in Wuhan, China, in December 2019. Since then, several SARS-CoV-2 mutants have rapidly disseminated as exemplified by the community spread of the recent omicron variant. The disease already attained a pandemic status with ever-dwindling mortality even after two and half years of identification and considerable vaccination. Aspergillosis, candidiasis, cryptococcosis and mucormycosis are the prominent fungal infections experienced by the majority of SARS-CoV-2 high-risk patients. In its entirety, COVID-19's nexus with these fungal infections may worsen the intricacies in the already beleaguered high-risk patients, making this a topic of substantial clinical concern. Thus, thorough knowledge of the subject is necessary. This article focuses on the concomitant fungal infection(s) in COVID-19 patients, taking into account their underlying causes, the screening methods, manifested drug resistance, and long-term effects. The information and knowledge shared herein could be crucial for the management of critically ill, aged, and immunocompromised SARS-CoV-2 patients who have had secondary fungal infections (SFIs).
Keywords: Aspergillosis; COVID-19; Candidiasis; Cryptococcosis; Drug resistance; Fungal infection; Mucormycosis; SARS-CoV-2.
. 2023 Jun 24.
doi: 10.1007/s43440-023-00506-z. Online ahead of print. Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments
Raj Singh[SUP] #[/SUP][SUP] 1 [/SUP], Parth Malik[SUP] #[/SUP][SUP] 2 [/SUP], Mukesh Kumar[SUP] 1 [/SUP], Raman Kumar[SUP] 1 [/SUP], Md Shamshir Alam[SUP] 3 [/SUP], Tapan Kumar Mukherjee[SUP] 4 5 [/SUP]
Affiliations
- PMID: 37354313
- DOI: 10.1007/s43440-023-00506-z
The earliest documented COVID-19 case caused by the SARS-CoV-2 coronavirus occurred in Wuhan, China, in December 2019. Since then, several SARS-CoV-2 mutants have rapidly disseminated as exemplified by the community spread of the recent omicron variant. The disease already attained a pandemic status with ever-dwindling mortality even after two and half years of identification and considerable vaccination. Aspergillosis, candidiasis, cryptococcosis and mucormycosis are the prominent fungal infections experienced by the majority of SARS-CoV-2 high-risk patients. In its entirety, COVID-19's nexus with these fungal infections may worsen the intricacies in the already beleaguered high-risk patients, making this a topic of substantial clinical concern. Thus, thorough knowledge of the subject is necessary. This article focuses on the concomitant fungal infection(s) in COVID-19 patients, taking into account their underlying causes, the screening methods, manifested drug resistance, and long-term effects. The information and knowledge shared herein could be crucial for the management of critically ill, aged, and immunocompromised SARS-CoV-2 patients who have had secondary fungal infections (SFIs).
Keywords: Aspergillosis; COVID-19; Candidiasis; Cryptococcosis; Drug resistance; Fungal infection; Mucormycosis; SARS-CoV-2.